drugset / Trial / NCT03273413

Statin Therapy in Patients With Early Stage ADPKD

NCT03273413

Phase 4 Active not recruiting 150 enrolled University of Colorado, Denver
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.

Timeline

Start
2017-08-31
Primary completion
2024-03-25
Completion
2025-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pravastatin Small molecule 40 mg